Dynavax Technologies Corporation (NASDAQ: DVAX) is 8.83% higher on its value in year-to-date trading and has touched a low of $7.26 and a high of $17.48 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The DVAX stock was last observed hovering at around $11.30 in the last trading session, with the day’s gains setting it 0.28% off its average median price target of $22.00 for the next 12 months. It is also 58.64% off the consensus price target high of $28.00 offered by 6 analysts, but current levels are 42.1% higher than the price target low of $20.00 for the same period.
Currently trading at $11.58, the stock is 6.62% and -0.45% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.84 million and changing 2.48% at the moment leaves the stock -1.17% off its SMA200. DVAX registered -11.94% loss for a year compared to 6-month loss of -21.65%.
The stock witnessed a 3.58% gain in the last 1 month and extending the period to 3 months gives it a 12.21%, and is 2.03% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 2.86% over the week and 3.84% over the month.
Dynavax Technologies Corporation (DVAX) has around 311 employees, a market worth around $1.46B and $733.30M in sales. Current P/E ratio is 5.78. Profit margin for the company is 43.70%. Distance from 52-week low is 59.50% and -33.75% from its 52-week high. The company has generated returns on investments over the last 12 months (29.00%).
Dynavax Technologies Corporation (DVAX) Analyst Forecasts
Analyst recommendations provided by FactSet shows that the consensus forecast for Dynavax Technologies Corporation (DVAX) is a “Buy”. 6 analysts offering their recommendations for the stock have an average rating of 1.80, where 0 rate it as a Hold and 0 think it is a “Overweight”. 6 of the analysts rate the stock as a “Buy”. 0 analysts have rated the stock as a Sell or Underperform.
Dynavax Technologies Corporation is expected to release its quarterly report on 05/10/2023.The EPS is expected to grow by 172.60% this year.
Dynavax Technologies Corporation (DVAX) Top Institutional Holders
The shares outstanding are 127.58M, and float is at 127.26M with Short Float at 10.06%.
Dynavax Technologies Corporation (DVAX) Insider Activity
A total of 20 insider transactions have happened at Dynavax Technologies Corporation (DVAX) in the last six months, with sales accounting for 11 and purchases happening 9 times. The most recent transaction is an insider sale by Hack Andrew A. F.,the company’sDirector. SEC filings show that Hack Andrew A. F. sold 1,500,000 shares of the company’s common stock on Dec 06 at a price of $11.60 per share for a total of $17.4 million. Following the sale, the insider now owns 3.92 million shares.
Dynavax Technologies Corporation disclosed in a document filed with the SEC on Nov 08 that Novack David F (President & COO) sold a total of 52,204 shares of the company’s common stock. The trade occurred on Nov 08 and was made at $12.47 per share for $0.65 million. Following the transaction, the insider now directly holds 2066.0 shares of the DVAX stock.
Still, SEC filings show that on Aug 15, Hack Andrew A. F. (Director) disposed off 3,000,000 shares at an average price of $14.68 for $44.04 million. The insider now directly holds 5,415,000 shares of Dynavax Technologies Corporation (DVAX).
Dynavax Technologies Corporation (DVAX): Who are the competitors?
The company’s main competitors (and peers) include AstraZeneca PLC (AZN) that is trading 12.36% up over the past 12 months and Biogen Inc. (BIIB) that is 29.22% higher over the same period. Pfizer Inc. (PFE) is -16.78% down on the 1-year trading charts.